Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials.
Wessels AM, Tariot PN, Zimmer JA, Selzler KJ, Bragg SM, Andersen SW, Landry J, Krull JH, Downing AM, Willis BA, Shcherbinin S, Mullen J, Barker P, Schumi J, Shering C, Matthews BR, Stern RA, Vellas B, Cohen S, MacSweeney E, Boada M, Sims JR. Wessels AM, et al. Among authors: schumi j. JAMA Neurol. 2020 Feb 1;77(2):199-209. doi: 10.1001/jamaneurol.2019.3988. JAMA Neurol. 2020. PMID: 31764959 Free PMC article. Clinical Trial.
Development Review of the BACE1 Inhibitor Lanabecestat (AZD3293/LY3314814).
Sims JR, Selzler KJ, Downing AM, Willis BA, Aluise CD, Zimmer J, Bragg S, Andersen S, Ayan-Oshodi M, Liffick E, Eads J, Wessels AM, Monk S, Schumi J, Mullen J. Sims JR, et al. Among authors: schumi j. J Prev Alzheimers Dis. 2017;4(4):247-254. doi: 10.14283/jpad.2017.38. J Prev Alzheimers Dis. 2017. PMID: 29181490 Review.
Disease Modification in Alzheimer's Disease: Current Thinking.
Liu-Seifert H, Schumi J, Miao X, Tian Y, Rabbia M, Andersen SW, Wilson S, Li W, Entsuah R. Liu-Seifert H, et al. Among authors: schumi j. Ther Innov Regul Sci. 2020 Mar;54(2):396-403. doi: 10.1007/s43441-019-00068-4. Epub 2020 Jan 6. Ther Innov Regul Sci. 2020. PMID: 32072596 Review.
Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial.
Tardif JC, McMurray JJ, Klug E, Small R, Schumi J, Choi J, Cooper J, Scott R, Lewis EF, L'Allier PL, Pfeffer MA; Aggressive Reduction of Inflammation Stops Events (ARISE) Trial Investigators. Tardif JC, et al. Among authors: schumi j. Lancet. 2008 May 24;371(9626):1761-8. doi: 10.1016/S0140-6736(08)60763-1. Lancet. 2008. PMID: 18502300 Clinical Trial.
The Tinnitus Retraining Therapy Trial (TRTT): study protocol for a randomized controlled trial.
Scherer RW, Formby C, Gold S, Erdman S, Rodhe C, Carlson M, Shade D, Tucker M, Sensinger LM, Hughes G, Conley GS, Downey N, Eades C, Jylkka M, Haber-Perez A, Harper C, Russell SK, Sierra-Irizarry B, Sullivan M; Tinnitus Retraining Therapy Trial Research Group. Scherer RW, et al. Trials. 2014 Oct 15;15:396. doi: 10.1186/1745-6215-15-396. Trials. 2014. PMID: 25319676 Free PMC article. Clinical Trial.
Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans.
Ericson E, Bergenholm L, Andréasson AC, Dix CI, Knöchel J, Hansson SF, Lee R, Schumi J, Antonsson M, Fjellström O, Nasr P, Liljeblad M, Carlsson B, Kechagias S, Lindén D, Ekstedt M. Ericson E, et al. Among authors: schumi j. Hepatol Commun. 2022 Oct;6(10):2689-2701. doi: 10.1002/hep4.2032. Epub 2022 Jul 14. Hepatol Commun. 2022. PMID: 35833455 Free PMC article.
13 results